Nothing Special   »   [go: up one dir, main page]

WO2018200812A1 - Conjugués d'anticorps comprenant un agoniste de sting - Google Patents

Conjugués d'anticorps comprenant un agoniste de sting Download PDF

Info

Publication number
WO2018200812A1
WO2018200812A1 PCT/US2018/029570 US2018029570W WO2018200812A1 WO 2018200812 A1 WO2018200812 A1 WO 2018200812A1 US 2018029570 W US2018029570 W US 2018029570W WO 2018200812 A1 WO2018200812 A1 WO 2018200812A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
alkynyl
alkenyl
crc
independently selected
Prior art date
Application number
PCT/US2018/029570
Other languages
English (en)
Inventor
Thomas W. Dubensky Jr.
Jacob Robert BRUML
Stephen CANHAM
Charles Y. CHO
Kelsey GAUTHIER
Laura Hix GLICKMAN
Xueshi Hao
David Kanne
Shailaja Kasibhatla
George Edwin KATIBAH
Thanh Ngoc Lan LE
Justin Leong
Jeffrey Mckenna
Sarah McWHIRTER
Chudi Obioma Ndubaku
Weijia Ou
Leonard Sung
George Scott Tria
Tetsuo Uno
Tom Yao-Hsiang Wu
Yongqin Wan
Original Assignee
Novartis Ag
Aduro Biotech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Aduro Biotech, Inc. filed Critical Novartis Ag
Priority to EP18724677.2A priority Critical patent/EP3615080A1/fr
Priority to JP2019558397A priority patent/JP2020517700A/ja
Priority to CN201880043438.4A priority patent/CN110799218A/zh
Publication of WO2018200812A1 publication Critical patent/WO2018200812A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • C07K9/003—Peptides being substituted by heterocyclic radicals, e.g. bleomycin, phleomycin

Definitions

  • n is an integer from 1 to 20;
  • n is an integer from 1 to 8.
  • n is an integer from 1 to 8.
  • the luciferase reporter gene is the 5xlSRE-mlFNb-GL4 reporter gene and the STING-expressing cell is a cell expressing wild-type human STING protein, and optionally the STING agonist activity is determined by the hSTING wt assay described in Table 7.
  • the immunoconjugate stimulates IP-10 secretion from a STING-expressing cell targeted by the Ab at an EC50 of 5 nanomolar (nM) or less in an IP-10 secretion assay.
  • R 2 and R 3 are connected to form CrCgalkylene, C 2 -C 6 alkenylene, C 2 -C 6 alkynylene, - O-CrCsalkylene, -0-C 2 -C 6 alkenylene, -0-C 2 -C 6 alkynylene, such that when R 2 and R 3 are connected, the 0 is bound at the R 3 position;
  • R 4 and R 3 are connected to form CrCsalkylene, C 2 -C 6 alkenylene, C 2 -C 6 alkynylene, - O-CrCsalkylene, -0-C 2 -C 6 alkenylene, -0-C 2 -C 6 alkynylene, such that when R 4 and R 3 are connected, the 0 is bound at the R 3 position;
  • R and R are connected to form C ⁇ Csalkylene, C 2 -C 3 alkenylene, C 2 -C 6 alkynylene, -O-CrCealkylene, -0-C 2 -C 6 alkenylene, -0-C 2 -C 6 alkynylene, such that when R 4a and R 3a are connected, the 0 is bound at the R 3a position;
  • X D is C, and each Z 4 is N;
  • Y 10 is -CH 2 -, -NH-, -0- or -S;
  • X 4 is -0(CH 2 ) n SSC(R 12 ) 2 (CH 2 ) n - or -(CH 2 ) n C(R 12 ) 2 SS(CH 2 ) n O-;
  • X 5 is where the ** indicates orientation toward the Drug moiety;
  • each R 111 is independently selected from H, C r C 6 alkyl, F, CI, -NH 2 , -OCH 3 , -OCH 2 CH 3 , -
  • FIG. 7 is a line graph showing the anti-HER2 mAb1 -C1 conjugate inhibits HCC1954 breast tumor growth in mice.
  • FIG. 1 1 illustrates certain compounds which can be used as a Drug moiety.
  • C 2 -C 6 alkynyl refers to a bivalent straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one triple bond, having from two to six carbon atoms.
  • C r C 6 hydroxyalkyl refers to a C 1-6 alkyl radical as defined above, wherein one of the hydrogen atoms of the C 1-6 alkyl radical is replaced by OH.
  • hydroxyC ⁇ alkyl include, but are not limited to, hydroxy-methyl, 2-hydroxy-ethyl, 2-hydroxy- propyl, 3-hydroxy-propyl and 5-hydroxy-pentyl
  • C 3 -C 8 cycloalkyl refers to a saturated, monocyclic, fused bicyclic, fused tricyclic or bridged polycyclic ring system.
  • Non-limiting examples of fused bicyclic or bridged polycyclic ring systems include bicyclo[1 .1 .1 ]pentane, bicyclo[2.1.1]hexane, bicyclo[2.2.1]heptane, bicyclo[3.1.1]heptane, bicyclo[3.2.1 ]octane, bicyclo[2.2.2]octane and adamantanyl.
  • Non-limiting examples monocyclic C 3 -C 8 cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl groups.
  • the C 2 - C 6 haloalkynyl groups can be diC 2 -C 6 haloalkynyl wherein such C 2 -C 6 haloalkynyl groups can have two halo atoms independently selected from iodo, bromo, chloro or fluoro.
  • the C 2 -C 6 haloalkynyl groups can be polyC 2 -C 6 haloalkynyl wherein such C 2 -C 6 haloalkenyl groups can have two or more of the same halo atoms or a combination of two or more different halo atoms.
  • heterocyclyl includes partially saturated or aromatic monocyclic or fused bicyclic heterocyclyl containing from 5-10 ring members selected from carbon atoms and 1 to 5 heteroatoms, and each heteroatoms is independently selected from O, N or S. In a preferred embodiment, the heteroatoms are nitrogen.
  • substituents include oxo, halo, C 1-6 alkyl, C ⁇ alkoxy, amino, C ⁇ alkylamino, di-C ⁇ alkylamino.
  • the heterocyclic group can be attached at a heteroatom or a carbon atom.
  • Heterocyclyl also includes 6-membered monocyclic partially saturated ring having 1-3 heteroatoms (preferably nitrogen).
  • Examples of partially saturated monocyclic heterocyclyl are pyrimidine-one and pyrimidine-dione, specifically pyrimidin-2(1 H)-one and pyrimidin-1 -yl-2,4(1 H, 3H)-dione.
  • tautomer is used to designate 2 molecules with the same molecular formula but different connectivity, which can interconvert in a rapid equilibrium.
  • phosporothioic acid and phosphoric acid moieties can exist in the respective equilibrium as shown below.
  • VH heavy chain variable domain
  • HCDR1 e.g., insertion(s) after position 35
  • homologous refers to the subunit sequence identity between two polymeric molecules, e.g., between two nucleic acid molecules, such as, two DNA molecules or two RNA molecules, or between two polypeptide molecules.
  • two nucleic acid molecules such as, two DNA molecules or two RNA molecules
  • polypeptide molecules between two polypeptide molecules.
  • a subunit position in both of the two molecules is occupied by the same monomeric subunit; e.g., if a position in each of two DNA molecules is occupied by adenine, then they are homologous or identical at that position.
  • the homology between two sequences is a direct function of the number of matching or homologous positions; e.g., if half (e.g., five positions in a polymer ten subunits in length) of the positions in two sequences are homologous, the two sequences are 50% homologous; if 90% of the positions (e.g., 9 of 10), are matched or homologous, the two sequences are 90% homologous.
  • Percentage of "sequence identity" can be determined by comparing two optimally aligned sequences over a comparison window, where the fragment of the amino acid sequence in the comparison window may comprise additions or deletions (e.g., gaps or overhangs) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences.
  • the percentage can be calculated by determining the number of positions at which the identical amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison, and multiplying the result by 100 to yield the percentage of sequence identity.
  • the output is the percent identity of the subject sequence with respect to the query sequence.
  • the percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.
  • an optical isomer or "a stereoisomer”, as used herein, refers to any of the various stereo isomeric configurations which may exist for a given compound of the present invention and includes geometric isomers. It is understood that a substituent may be attached at a chiral center of a carbon atom.
  • the term “chiral” refers to molecules which have the property of non-superimposability on their mirror image partner, while the term “achiral” refers to molecules which are superimposable on their mirror image partner. Therefore, the invention includes enantiomers, diastereomers or racemates of the compound. "Enantiomers” are a pair of stereoisomers that are non- superimposable mirror images of each other.
  • P-cadherin also refers to proteins and amino acid sequences that over their full length have at least about 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with the amino acid sequence of the above GenBank accession Nos.
  • pharmaceutically acceptable salt refers to a salt which does not abrogate the biological activity and properties of the compounds of the invention, and does not cause significant irritation to a subject to which it is administered.
  • STING agonist refers to a compound or antibody conjugate capable of binding to STING and activating STING.
  • Activation of STING activity may include, for example, stimulation of inflammatory cytokines, including interferons, such as type 1 interferons, including IFN-a, IFN- ⁇ , type 3 interferons, e.g., IFN , IP10, TNF, IL-6, CXCL9, CCL4, CXCL11 , CCL5, CCL3, or CCL8.
  • interferons such as type 1 interferons, including IFN-a, IFN- ⁇ , type 3 interferons, e.g., IFN , IP10, TNF, IL-6, CXCL9, CCL4, CXCL11 , CCL5, CCL3, or CCL8.
  • terapéuticaally effective amount or “therapeutically effective dose” interchangeably refers to an amount sufficient to effect the desired result (i.e., reduction or inhibition of an enzyme or a protein activity, amelioration of symptoms, alleviation of symptoms or conditions, delay of disease progression, a reduction in tumor size, inhibition of tumor growth, prevention of metastasis, inhibition or prevention of viral, bacterial, fungal or parasitic infection).
  • a therapeutically effective amount does not induce or cause undesirable side effects.
  • a therapeutically effective amount induces or causes side effects but only those that are acceptable by the healthcare providers in view of a patient's condition.
  • a therapeutically effective amount can be determined by first administering a low dose, and then incrementally increasing that dose until the desired effect is achieved.
  • Y 7 is 0 or S
  • CrCshaloalkyl C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, -0(C r C 6 alkyl), -0(C 2 -C 3 alkenyl), - 0(C 2 -C 6 alkynyl), -OC(0)OCrC 6 alkyl, -OC(0)OC 2 -C 6 alkenyl, -OC(0)OC 2 -C 6 alkynyl, - OC(0)C r C 6 alkyl, -OC(0)C 2 -C 6 alkenyl and -OC(0)C 2 -C 6 alkynyl of R 3 are substituted by 0,1 , 2 or 3 substituents independently selected from F, CI, Br, I, OH, CN, and N 3 ;
  • R 3a and R 6a are connected to form Crdalkylene, C 2 -C 6 alkenylene, C 2 - C 6 alkynylene, -0-C r C 6 alkylene, -0-C 2 -C 6 alkenylene, -0-C 2 -C 6 alkynylene, such that when R 3a and R 6a are connected, the O is bound at the R 3a position;
  • R 2 and R 3 are connected to form d-Calkylene, C 2 -C 6 alkenylene, C 2 -
  • R 5 and R 6 are connected to form C ⁇ Cealkylene, C 2 -C 6 alkenylene, C 2 - C 6 alkynylene, -0-C r C 6 alkylene, -0-C 2 -C 6 alkenylene, -0-C 2 -C 6 alkynylene, such that when R 5 and R 6 are connected, the 0 is bound at the R 5 position;
  • R 5a and R 7a are connected to form CrCsalkylene, C 2 -C 6 alkenylene, C 2 - C 6 alkynylene, -0-C r C 6 alkylene, -0-C 2 -C 6 alkenylene, -0-C 2 -C 6 alkynylene, such that when R 5a and R 7a are connected, the O is bound at the R 5a position;
  • R 6 and R 6a are H
  • R 8 , R 9 , R 8a and R 9a are independently H or C r C 6 alkyl
  • Embodiment 1 , 2 or 3 wherein:
  • R 8 , R 9 , R 8a and R 9a are independently H or C r C 6 alkyl
  • Y 9 and Y 10 are 0 or S;
  • Embodiment 12 A compound of Formula (E), Formula (E-1) or Formula (E-2) of
  • Embodiment 1 , 2 or 3 wherein:
  • R 3a and R 4a is H and the other is selected from the group consisting of H, -OH, F, CI, Br, I, D, CD 3 , CN, N 3 , C r C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, CrCehaloalkyl, C 2 -
  • C 6 alkyl, -OC(0)OC 2 -C 6 alkenyl, -OC(0)OC 2 -C 6 alkynyl, -OC ⁇ CrCealkyl, -OC(0)C 2 - C 6 alkenyl and -OC(0)C 2 -C 6 alkynyl of R 3 or R 4 are substituted by 0, 1 , 2 or 3 substituents independently selected from F, CI, Br, I, OH, CN, and N 3 , and one of R 5 and R 7 is H and the other is selected from the group consisting of H, -OH, F, CI, Br, I, D, CD 3 , CN, N 3 , C r C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C r C 6 haloalkyl, C 2 - C 6 haloalkenyl, C 2 -C 6 haloalkynyl, -0(C r Csal
  • Embodiment 1 1, 2, 3 or 12 wherein:
  • Y 5 is O or S
  • Y 7 is O or S
  • R 3a , R a is H and the other is H, OH, OCH 3 or F;
  • R 3 , R 4 is H and the other is H, OH, OCH 3 or F;
  • R 5 and R 7 are H and the other is H, OH, OCH 3 or F, and
  • Embodiment 14 A compound of Formula (F), Formula (F-1) or Formula (F-2) of
  • R 2 and R 2a are H; each R e and R ea are H;
  • each R 7a and R 7 are H;
  • R 8 , R 9 , R 8a and R 9a are independently H or C r C 6 alkyl
  • R 3a and R a is H and the other is selected from the group consisting of H, -OH, F, CI, Br, I, D, CD 3 , CN, N 3 , C r C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C r C 6 haloalkyl, C 2 -
  • C 6 alkenyl and -OC(0)C 2 -C 6 alkynyl of R 3 or R 4 are substituted by 0, 1 , 2 or 3 substituents independently selected from F, CI, Br, I, OH, CN, and N 3 , and
  • R 5 is selected from the group consisting of H, -OH, F, CI, Br, I, D, CD 3 , CN, N 3 , C r
  • Embodiment 15 A compound of Formula (F), Formula (F-1) or Formula (F-2) of
  • Embodiment 1 1, 2, 3 or 12 wherein:
  • Y 1 and Y 2 are 0, CH 2 or S;
  • each Y 3 is OH, 0 " , OR 10 , N(R 10 ) 2 , SH or S " ;
  • R 2 , R 2a , R 6 , R 6a , R 6 , R 7 and R 7a are H;
  • R 3 , R 4 is H and the other is H, OH, OCH 3 or F;
  • R is substituted with 0, 1 , 2 or 3 substituents independently selected from F, CI, Br, OH, SH, NH 2 , D, CD 3 , C r C s alkyl, C r
  • Y 3 is OH, 0 " , OR 10 , N(R 10 ) 2 , SH or S " ;
  • each R 6 is independently selected from the group consisting of H, -OH, F, CI, Br, I, D, CD 3 , CN, N 3 , C r C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, CrCehaloalkyl, C 2 -C 3 haloalkenyl, C 2 -
  • CrCshaloalkyl C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, -0(C r C 6 alkyl), -0(C 2 -C 3 alkenyl), - 0(C 2 -C 6 alkynyl), -OC(0)OCrC 6 alkyl, -0C(0)0C 2 -C 6 alkenyl, -0C(0)0C 2 -C 6 alkynyl, - OC(0)C r C 6 alkyl, -OC(0)C 2 -C 6 alkenyl and -OC(0)C 2 -C 6 alkynyl of R s are substituted by 0, 1 , 2 or 3 substituents independently selected from F, CI, Br, I, OH, CN, and N 3 ;

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des immunoconjugués comprenant des agonistes de STING. L'invention concerne également des méthodes de fabrication des immunoconjugués et des méthodes de traitement du cancer à l'aide des immunoconjugués.
PCT/US2018/029570 2017-04-28 2018-04-26 Conjugués d'anticorps comprenant un agoniste de sting WO2018200812A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP18724677.2A EP3615080A1 (fr) 2017-04-28 2018-04-26 Conjugués d'anticorps comprenant un agoniste de sting
JP2019558397A JP2020517700A (ja) 2017-04-28 2018-04-26 Ｓｔｉｎｇアゴニストを含む抗体コンジュゲート
CN201880043438.4A CN110799218A (zh) 2017-04-28 2018-04-26 包含sting激动剂的抗体缀合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762491879P 2017-04-28 2017-04-28
US62/491,879 2017-04-28

Publications (1)

Publication Number Publication Date
WO2018200812A1 true WO2018200812A1 (fr) 2018-11-01

Family

ID=62165655

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/029570 WO2018200812A1 (fr) 2017-04-28 2018-04-26 Conjugués d'anticorps comprenant un agoniste de sting

Country Status (5)

Country Link
EP (1) EP3615080A1 (fr)
JP (1) JP2020517700A (fr)
CN (1) CN110799218A (fr)
AR (1) AR113224A1 (fr)
WO (1) WO2018200812A1 (fr)

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020089815A1 (fr) * 2018-10-31 2020-05-07 Novartis Ag Conjugués d'anticorps comprenant un agoniste de sting
WO2020092617A1 (fr) * 2018-10-31 2020-05-07 Novartis Ag Conjugués d'anticorps dc-sign comprenant des agonistes de sting
WO2020227159A2 (fr) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Métodes de modulation de l'activité immunitaire
WO2020229982A1 (fr) 2019-05-10 2020-11-19 Takeda Pharmaceutical Company Limited Conjugués anticorps-médicament
WO2020236817A2 (fr) 2019-05-20 2020-11-26 Novartis Ag Conjugués anticorps-médicament inhibiteurs de mcl-1 et méthodes d'utilisation
CN112439075A (zh) * 2019-09-04 2021-03-05 乐高化学生物科学股份有限公司 包含抗人类ror1抗体的抗体-药物结合物和其用途
WO2021046426A1 (fr) * 2019-09-06 2021-03-11 Sperovie Biosciences, Inc. Agonistes de sting dinucléotidiques cycliques attachés à un pd-1 ou à des anticorps ctla-4
US10980825B2 (en) 2016-12-01 2021-04-20 Takeda Pharmaceutical Company Limited Cyclic dinucleotide
US11033635B2 (en) 2019-07-19 2021-06-15 Immunesensor Therapeutics, Inc. Antibody-STING agonist conjugates and their use in immunotherapy
WO2021132166A1 (fr) * 2019-12-23 2021-07-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 Procédé de production d'un conjugué anticorps-médicament à base d'éribuline
US20210205348A1 (en) * 2018-06-01 2021-07-08 Eisai R&D Management Co., Ltd. Methods for the Treatment of Bladder Cancer
CN113195541A (zh) * 2018-12-21 2021-07-30 诺华股份有限公司 针对pmel17的抗体及其缀合物
WO2021177438A1 (fr) * 2020-03-06 2021-09-10 第一三共株式会社 Conjugué anticorps-médicament comprenant un nouveau dérivé de dinucléotide cyclique
WO2021202984A1 (fr) * 2020-04-02 2021-10-07 Mersana Therapeutics, Inc. Conjugués anticorps-médicament comprenant des agonistes de sting
WO2021206158A1 (fr) 2020-04-10 2021-10-14 小野薬品工業株式会社 Méthode de cancérothérapie
US11155567B2 (en) 2019-08-02 2021-10-26 Mersana Therapeutics, Inc. Sting agonist compounds and methods of use
WO2021216572A1 (fr) 2020-04-20 2021-10-28 Massachusetts Institute Of Technology Compositions lipidiques pour l'administration de composés agonistes de sting et leurs utilisations
WO2021232019A1 (fr) 2020-05-15 2021-11-18 Immunesensor Therapeutics, Inc. Polythérapies à agoniste de sting assorties d'inhibiteurs de points de contrôle immunitaires
JP2021532172A (ja) * 2018-07-10 2021-11-25 スペロヴィー バイオサイエンシズ，インコーポレーテッド 疾患を治療するための化合物、組成物及び方法
WO2022097117A1 (fr) 2020-11-09 2022-05-12 Takeda Pharmaceutical Company Ltd. Conjugués anticorps-médicament
WO2022217022A1 (fr) 2021-04-10 2022-10-13 Profoundbio Us Co. Agents de liaison à folr1, conjugués de ceux-ci et leurs procédés d'utilisation
JP2022545006A (ja) * 2019-08-21 2022-10-24 ザ スクリプス リサーチ インスティテュート インターフェロン遺伝子の刺激因子ｓｔｉｎｇの二環式アゴニスト
WO2022226317A1 (fr) 2021-04-23 2022-10-27 Profoundbio Us Co. Anticorps anti-cd70, leurs conjugués et leurs procédés d'utilisation
WO2022223619A1 (fr) 2021-04-20 2022-10-27 Institut Curie Compositions et procédés destinés à être utilisés en immunothérapie
US11542293B2 (en) 2017-11-10 2023-01-03 Takeda Pharmaceutical Company Limited Sting modulator compounds, and methods of making and using
WO2023280227A2 (fr) 2021-07-06 2023-01-12 Profoundbio Us Co. Lieurs, lieurs de médicament, conjugués de ceux-ci et leurs méthodes d'utilisation
WO2023004440A2 (fr) 2021-07-23 2023-01-26 Immunesensor Therapeutics, Inc. Polythérapies à base d'agonistes de sting comprenant des cytokines
US11584774B2 (en) 2017-09-11 2023-02-21 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
CN115867322A (zh) * 2020-03-31 2023-03-28 奥隆制药 新降解剂缀合物
WO2023109942A1 (fr) * 2021-12-17 2023-06-22 Jacobio Pharmaceuticals Co., Ltd. Constructions lieurs-composés comprenant de nouveaux composés utiles en tant qu'agonistes de sting et leurs utilisations
US11707531B2 (en) 2017-09-11 2023-07-25 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
US11730817B2 (en) * 2017-12-29 2023-08-22 Invivogen Pro-cyclic dinucleotides and pro-cyclic dinucleotide conjugates for cytokine induction
US11787833B2 (en) 2019-05-09 2023-10-17 Aligos Therapeutics, Inc. Modified cyclic dinucleoside compounds as sting modulators
US11827703B2 (en) 2018-05-09 2023-11-28 Legochem Biosciences, Inc. Compositions and methods related to anti-CD19 antibody drug conjugates
WO2024020164A2 (fr) 2022-07-21 2024-01-25 Firefly Bio, Inc. Agonistes du récepteur des glucocorticoïdes et leurs conjugués
US11975076B2 (en) 2015-11-25 2024-05-07 Legochem Biosciences, Inc. Antibody-drug conjugates comprising branched linkers and methods related thereto
WO2024100449A1 (fr) * 2022-11-08 2024-05-16 Legochem Biosciences, Inc. Agonistes de sting
WO2024189481A1 (fr) 2023-03-10 2024-09-19 Novartis Ag Conjugués anticorps-médicament inhibiteurs de panras et leurs procédés d'utilisation
WO2024201004A1 (fr) 2023-03-24 2024-10-03 Prostate Cancer Research Thérapie combinatoire d'il-15

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111592570B (zh) * 2020-05-15 2022-04-29 清华大学 新型sting激动剂及其制备方法和应用
WO2024153127A1 (fr) * 2023-01-18 2024-07-25 泰励生物科技（上海）有限公司 Conjugué anticorps-médicament et son utilisation

Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703199B1 (en) 1997-06-12 2004-03-09 Research Corporation Technologies, Inc. Artificial antibody polypeptides
WO2007070598A2 (fr) 2005-12-13 2007-06-21 Spring Bank Promedicaments nucleotide et oligonucleotide
US20090274713A1 (en) 2008-04-30 2009-11-05 Immunogen Inc. Cross-linkers and their uses
WO2014083505A1 (fr) 2012-11-30 2014-06-05 Novartis Ag Procédés pour la fabrication de conjugués à partir de protéines contenant du disulfure
WO2014093936A1 (fr) 2012-12-13 2014-06-19 Aduro Biotech, Inc. Compositions comprenant des dinucléotides cycliques de purine présentant des stéréochimies définies et procédés pour leur préparation et leur utilisation
WO2014124316A2 (fr) 2013-02-08 2014-08-14 Irm Llc Sites spécifiques de modification d'anticorps pour fabriquer des immunoconjugués
WO2014179335A1 (fr) 2013-04-29 2014-11-06 Memorial Sloan Kettering Cancer Center Compositions et procédés pour altérer la signalisation par un second messager
WO2014189805A1 (fr) 2013-05-18 2014-11-27 Auro Biotech, Inc. Compositions et procédés d'activation de la signalisation dépendante de « stimulateur de gènes d'interféron »
WO2015074145A1 (fr) 2013-11-22 2015-05-28 Brock University Utilisation de dinucléotides cycliques fluorés comme adjuvants de vaccin oral
US20150158886A1 (en) 2013-12-06 2015-06-11 Rutgers, The State University Of New Jersey Cyclic dinucleosides
WO2015185565A1 (fr) 2014-06-04 2015-12-10 Glaxosmithkline Intellectual Property Development Limited Di-nucléotides cycliques utilisés comme modulateurs de sting
WO2016096174A1 (fr) 2014-12-16 2016-06-23 Invivogen Dinucléotides cycliques fluorés utilisables en vue de l'induction des cytokines
WO2016145102A1 (fr) 2015-03-10 2016-09-15 Aduro Biotech, Inc. Compositions et procédés d'activation de la signalisation dépendante de « stimulateur de gènes d'interféron »
WO2016161372A1 (fr) * 2015-04-01 2016-10-06 President And Fellows Of Harvard College Immunoconjugués pour la programmation ou reprogrammation de cellules
WO2017004499A1 (fr) 2015-07-02 2017-01-05 Spring Bank Pharmaceuticals, Inc. Compositions et méthodes de traitement d'une infection virale
WO2017011622A1 (fr) 2015-07-14 2017-01-19 Spring Bank Pharmaceuticals, Inc. Composés et compositions qui induisent rig-i et d'autres récepteurs de reconnaissance de motifs
WO2017027646A1 (fr) 2015-08-13 2017-02-16 Merck Sharp & Dohme Corp. Composés de di-nucléotide cyclique en tant qu'agonistes sting (stimulateur de gène interféron)
CN106540256A (zh) * 2016-03-27 2017-03-29 聊城市奥润生物医药科技有限公司 环二核苷酸-脂质体偶联单克隆抗体在抗肿瘤中的应用
WO2017100305A2 (fr) * 2015-12-07 2017-06-15 Opi Vi - Ip Holdco Llc Composition de conjugués d'agonistes-constructions d'anticorps et leurs procédés d'utilisation
WO2018009652A1 (fr) 2016-07-06 2018-01-11 Sperovie Biosciences, Inc. Composés, compositions et méthodes de traitement de maladie
WO2018009648A1 (fr) 2016-07-06 2018-01-11 Sperovie Biosciences, Inc. Composés, compositions et méthodes de traitement de maladie
WO2018013887A1 (fr) 2016-07-15 2018-01-18 Sperovie Biosciences, Inc. Composés, compositions et méthodes de traitement de maladie
WO2018013908A1 (fr) 2016-07-15 2018-01-18 Sperovie Biosciences, Inc. Composés, compositions et méthodes de traitement de maladie

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108025051B (zh) * 2015-07-29 2021-12-24 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法

Patent Citations (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703199B1 (en) 1997-06-12 2004-03-09 Research Corporation Technologies, Inc. Artificial antibody polypeptides
WO2007070598A2 (fr) 2005-12-13 2007-06-21 Spring Bank Promedicaments nucleotide et oligonucleotide
US20090274713A1 (en) 2008-04-30 2009-11-05 Immunogen Inc. Cross-linkers and their uses
WO2014083505A1 (fr) 2012-11-30 2014-06-05 Novartis Ag Procédés pour la fabrication de conjugués à partir de protéines contenant du disulfure
WO2014093936A1 (fr) 2012-12-13 2014-06-19 Aduro Biotech, Inc. Compositions comprenant des dinucléotides cycliques de purine présentant des stéréochimies définies et procédés pour leur préparation et leur utilisation
WO2014124316A2 (fr) 2013-02-08 2014-08-14 Irm Llc Sites spécifiques de modification d'anticorps pour fabriquer des immunoconjugués
WO2014179335A1 (fr) 2013-04-29 2014-11-06 Memorial Sloan Kettering Cancer Center Compositions et procédés pour altérer la signalisation par un second messager
WO2014189805A1 (fr) 2013-05-18 2014-11-27 Auro Biotech, Inc. Compositions et procédés d'activation de la signalisation dépendante de « stimulateur de gènes d'interféron »
WO2015074145A1 (fr) 2013-11-22 2015-05-28 Brock University Utilisation de dinucléotides cycliques fluorés comme adjuvants de vaccin oral
US20150158886A1 (en) 2013-12-06 2015-06-11 Rutgers, The State University Of New Jersey Cyclic dinucleosides
US9315523B2 (en) 2013-12-06 2016-04-19 Rutgers, The State University Of New Jersey Cyclic dinucleosides
WO2015185565A1 (fr) 2014-06-04 2015-12-10 Glaxosmithkline Intellectual Property Development Limited Di-nucléotides cycliques utilisés comme modulateurs de sting
WO2016096174A1 (fr) 2014-12-16 2016-06-23 Invivogen Dinucléotides cycliques fluorés utilisables en vue de l'induction des cytokines
WO2016145102A1 (fr) 2015-03-10 2016-09-15 Aduro Biotech, Inc. Compositions et procédés d'activation de la signalisation dépendante de « stimulateur de gènes d'interféron »
WO2016161372A1 (fr) * 2015-04-01 2016-10-06 President And Fellows Of Harvard College Immunoconjugués pour la programmation ou reprogrammation de cellules
WO2017004499A1 (fr) 2015-07-02 2017-01-05 Spring Bank Pharmaceuticals, Inc. Compositions et méthodes de traitement d'une infection virale
WO2017011622A1 (fr) 2015-07-14 2017-01-19 Spring Bank Pharmaceuticals, Inc. Composés et compositions qui induisent rig-i et d'autres récepteurs de reconnaissance de motifs
WO2017027646A1 (fr) 2015-08-13 2017-02-16 Merck Sharp & Dohme Corp. Composés de di-nucléotide cyclique en tant qu'agonistes sting (stimulateur de gène interféron)
WO2017027645A1 (fr) 2015-08-13 2017-02-16 Merck Sharp & Dohme Corp. Composés di-nucléotidiques cycliques en tant qu'agonistes de sting
WO2017100305A2 (fr) * 2015-12-07 2017-06-15 Opi Vi - Ip Holdco Llc Composition de conjugués d'agonistes-constructions d'anticorps et leurs procédés d'utilisation
CN106540256A (zh) * 2016-03-27 2017-03-29 聊城市奥润生物医药科技有限公司 环二核苷酸-脂质体偶联单克隆抗体在抗肿瘤中的应用
WO2018009652A1 (fr) 2016-07-06 2018-01-11 Sperovie Biosciences, Inc. Composés, compositions et méthodes de traitement de maladie
WO2018009648A1 (fr) 2016-07-06 2018-01-11 Sperovie Biosciences, Inc. Composés, compositions et méthodes de traitement de maladie
WO2018013887A1 (fr) 2016-07-15 2018-01-18 Sperovie Biosciences, Inc. Composés, compositions et méthodes de traitement de maladie
WO2018013908A1 (fr) 2016-07-15 2018-01-18 Sperovie Biosciences, Inc. Composés, compositions et méthodes de traitement de maladie

Non-Patent Citations (38)

* Cited by examiner, † Cited by third party
Title
"GenBank", Database accession no. AA14462
"GenBank", Database accession no. NG_007503.1
"GenBank", Database accession no. NG_009096
"GenBank", Database accession no. NG_009096.1
"GenBank", Database accession no. NM_001793.4
"GenBank", Database accession no. NP _001784
"GenBank", Database accession no. NP_ 001784
"GenBank", Database accession no. NP_ 001784.2
"GenBank", Database accession no. NP_001784
"GenBank", Database accession no. NP_001784.2
"Remington's Pharmaceutical Sciences, 18th ed.", 1990, MACK PRINTING COMPANY, pages: 1289 - 1329
AI-LAZIKANI ET AL., J. MAL. BIOL., vol. 273, 1997, pages 927 - 948
AI-LAZIKANI ET AL., JMB, vol. 273, 1997, pages 927 - 948
AL LAZIKANI ET AL., J. MOL. BIO., vol. 273, 1997, pages 927 948
ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 10
ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 3402
ANGEW. CHEM. INT. ED., vol. 54, 2015, pages 7492 - 7509
BIOCONJUGATE CHEMISTRY, vol. 26, 2015, pages 2554 - 2562
CHEN ET AL., CELL, vol. 147, 2011, pages 436 - 446
CHOTHIA ET AL., J. MOL. BIOL., vol. 196, 1987, pages 901 - 917
CHOTHIA ET AL., NATURE, vol. 342, 1989, pages 877 - 883
DUCRY ET AL., BIOCONIUQATE CHEM., vol. 21, 2010, pages 5 - 13
E. MEYERS; W. MILLER, CABIOS, vol. 4, 1989, pages 11 - 17
HOLLINGER; HUDSON, NATURE BIOTECHNOLOGY, vol. 23, 2005, pages 1126 - 1136
ISHIKAWA; BARBER, NATURE, vol. 455, no. 7213, 2008, pages 674 - 678
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
KABAT ET AL.: "Sequences of Proteins of Immunological Interest, 5th ed.", 1991, PUBLIC HEALTH SERVICE, NATIONAL INSTITUTES OF HEALTH
KATO ET AL., PLOS ONE, vol. 8, no. 10, 2013, pages e76983
KNAPPIK ET AL., J MOL BIOL, vol. 296, 2000, pages 57 - 86
LEFRANC, M.-P. ET AL., DEV. COMP. IMMUNOL., vol. 27, 2003, pages 55 - 77
LEFRANC, M.-P., THE IMMUNOLOGIST, vol. 7, 1999, pages 132 - 136
NEEDLEMAN; WUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 444 - 453
OU ET AL., PNAS, vol. 108, no. 26, 2011, pages 10437 - 42
OUYANG ET AL., IMMUNITY, vol. 36, 2012, pages 1073
STUDIER, PROTEIN EXPR PURIF., vol. 41, no. 1, May 2005 (2005-05-01), pages 207 - 34
TROUT ET AL., PROC. NATL. ACAD. SCI. USA, vol. 79, 1982, pages 626 - 629
UMEMOTO ET AL., INT. J. CANCER, vol. 43, 1989, pages 677 - 684
YI, PLOS ONE, vol. 8, no. 10, 21 October 2013 (2013-10-21), pages e77846

Cited By (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11975076B2 (en) 2015-11-25 2024-05-07 Legochem Biosciences, Inc. Antibody-drug conjugates comprising branched linkers and methods related thereto
US11666594B2 (en) 2016-12-01 2023-06-06 Takeda Pharmaceutical Company Limited Antibody-drug conjugates comprising a cyclic dinucleotide
US10980825B2 (en) 2016-12-01 2021-04-20 Takeda Pharmaceutical Company Limited Cyclic dinucleotide
US11584774B2 (en) 2017-09-11 2023-02-21 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
US11707531B2 (en) 2017-09-11 2023-07-25 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
US11542293B2 (en) 2017-11-10 2023-01-03 Takeda Pharmaceutical Company Limited Sting modulator compounds, and methods of making and using
US12054512B2 (en) 2017-11-10 2024-08-06 Takeda Pharmaceutical Company Limited Sting modulator compounds, and methods of making and using
US11730817B2 (en) * 2017-12-29 2023-08-22 Invivogen Pro-cyclic dinucleotides and pro-cyclic dinucleotide conjugates for cytokine induction
US11827703B2 (en) 2018-05-09 2023-11-28 Legochem Biosciences, Inc. Compositions and methods related to anti-CD19 antibody drug conjugates
US20210205348A1 (en) * 2018-06-01 2021-07-08 Eisai R&D Management Co., Ltd. Methods for the Treatment of Bladder Cancer
JP7440504B2 (ja) 2018-07-10 2024-02-28 エフ－スター・セラピューティクス・インコーポレイテッド 疾患を治療するための化合物、組成物及び方法
JP2021532172A (ja) * 2018-07-10 2021-11-25 スペロヴィー バイオサイエンシズ，インコーポレーテッド 疾患を治療するための化合物、組成物及び方法
WO2020092617A1 (fr) * 2018-10-31 2020-05-07 Novartis Ag Conjugués d'anticorps dc-sign comprenant des agonistes de sting
WO2020089815A1 (fr) * 2018-10-31 2020-05-07 Novartis Ag Conjugués d'anticorps comprenant un agoniste de sting
CN113195541A (zh) * 2018-12-21 2021-07-30 诺华股份有限公司 针对pmel17的抗体及其缀合物
CN113195541B (zh) * 2018-12-21 2024-08-30 诺华股份有限公司 针对pmel17的抗体及其缀合物
US11376272B2 (en) * 2019-05-03 2022-07-05 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
WO2020227159A2 (fr) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Métodes de modulation de l'activité immunitaire
US11787833B2 (en) 2019-05-09 2023-10-17 Aligos Therapeutics, Inc. Modified cyclic dinucleoside compounds as sting modulators
WO2020229982A1 (fr) 2019-05-10 2020-11-19 Takeda Pharmaceutical Company Limited Conjugués anticorps-médicament
CN114173824A (zh) * 2019-05-10 2022-03-11 武田药品工业株式会社 抗体药物缀合物
WO2020236817A2 (fr) 2019-05-20 2020-11-26 Novartis Ag Conjugués anticorps-médicament inhibiteurs de mcl-1 et méthodes d'utilisation
US11213592B2 (en) 2019-07-19 2022-01-04 Immunesensor Therapeutics, Inc. Antibody-sting agonist conjugates and their use in immunotherapy
US11033635B2 (en) 2019-07-19 2021-06-15 Immunesensor Therapeutics, Inc. Antibody-STING agonist conjugates and their use in immunotherapy
JP7576779B2 (ja) 2019-07-19 2024-11-01 イミューンセンサー セラピューティクス、インコーポレイテッド 抗体－ｓｔｉｎｇアゴニスト複合体および免疫療法におけるそれらの使用
US11155567B2 (en) 2019-08-02 2021-10-26 Mersana Therapeutics, Inc. Sting agonist compounds and methods of use
US11939343B2 (en) 2019-08-02 2024-03-26 Mersana Therapeutics, Inc. Sting agonist compounds and methods of use
JP2022545006A (ja) * 2019-08-21 2022-10-24 ザ スクリプス リサーチ インスティテュート インターフェロン遺伝子の刺激因子ｓｔｉｎｇの二環式アゴニスト
JP7414965B2 (ja) 2019-08-21 2024-01-16 ザ スクリプス リサーチ インスティテュート インターフェロン遺伝子の刺激因子ｓｔｉｎｇの二環式アゴニスト
CN112439075A (zh) * 2019-09-04 2021-03-05 乐高化学生物科学股份有限公司 包含抗人类ror1抗体的抗体-药物结合物和其用途
WO2021046426A1 (fr) * 2019-09-06 2021-03-11 Sperovie Biosciences, Inc. Agonistes de sting dinucléotidiques cycliques attachés à un pd-1 ou à des anticorps ctla-4
CN114828895A (zh) * 2019-12-23 2022-07-29 卫材R&D管理有限公司 制备基于艾日布林的抗体-药物缀合物的方法
WO2021132166A1 (fr) * 2019-12-23 2021-07-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 Procédé de production d'un conjugué anticorps-médicament à base d'éribuline
TWI851879B (zh) * 2020-03-06 2024-08-11 日商第一三共股份有限公司 含有新穎環狀雙核苷酸衍生物之抗體藥物共軛物
EP4115909A4 (fr) * 2020-03-06 2024-10-30 Daiichi Sankyo Co Ltd Conjugué anticorps-médicament comprenant un nouveau dérivé de dinucléotide cyclique
WO2021177438A1 (fr) * 2020-03-06 2021-09-10 第一三共株式会社 Conjugué anticorps-médicament comprenant un nouveau dérivé de dinucléotide cyclique
CN115867322A (zh) * 2020-03-31 2023-03-28 奥隆制药 新降解剂缀合物
US20220378749A1 (en) * 2020-04-02 2022-12-01 Mersana Therapeutics, Inc. Antibody drug conjugates comprising sting agonists
WO2021202984A1 (fr) * 2020-04-02 2021-10-07 Mersana Therapeutics, Inc. Conjugués anticorps-médicament comprenant des agonistes de sting
CN116196435A (zh) * 2020-04-02 2023-06-02 梅尔莎纳医疗公司 包含sting激动剂的抗体药物缀合物
EP4218826A3 (fr) * 2020-04-02 2023-10-25 Mersana Therapeutics, Inc. Conjugués anticorps-médicament comprenant des agonistes de sting
WO2021206158A1 (fr) 2020-04-10 2021-10-14 小野薬品工業株式会社 Méthode de cancérothérapie
WO2021216572A1 (fr) 2020-04-20 2021-10-28 Massachusetts Institute Of Technology Compositions lipidiques pour l'administration de composés agonistes de sting et leurs utilisations
WO2021232019A1 (fr) 2020-05-15 2021-11-18 Immunesensor Therapeutics, Inc. Polythérapies à agoniste de sting assorties d'inhibiteurs de points de contrôle immunitaires
WO2022097117A1 (fr) 2020-11-09 2022-05-12 Takeda Pharmaceutical Company Ltd. Conjugués anticorps-médicament
JP2023547289A (ja) * 2020-11-09 2023-11-10 武田薬品工業株式会社 抗体薬物コンジュゲート
JP7397996B2 (ja) 2020-11-09 2023-12-13 武田薬品工業株式会社 抗体薬物コンジュゲート
US11725024B2 (en) 2020-11-09 2023-08-15 Takeda Pharmaceutical Company Limited Antibody drug conjugates
WO2022217022A1 (fr) 2021-04-10 2022-10-13 Profoundbio Us Co. Agents de liaison à folr1, conjugués de ceux-ci et leurs procédés d'utilisation
WO2022223619A1 (fr) 2021-04-20 2022-10-27 Institut Curie Compositions et procédés destinés à être utilisés en immunothérapie
WO2022226317A1 (fr) 2021-04-23 2022-10-27 Profoundbio Us Co. Anticorps anti-cd70, leurs conjugués et leurs procédés d'utilisation
WO2023280227A2 (fr) 2021-07-06 2023-01-12 Profoundbio Us Co. Lieurs, lieurs de médicament, conjugués de ceux-ci et leurs méthodes d'utilisation
WO2023004440A2 (fr) 2021-07-23 2023-01-26 Immunesensor Therapeutics, Inc. Polythérapies à base d'agonistes de sting comprenant des cytokines
WO2023109942A1 (fr) * 2021-12-17 2023-06-22 Jacobio Pharmaceuticals Co., Ltd. Constructions lieurs-composés comprenant de nouveaux composés utiles en tant qu'agonistes de sting et leurs utilisations
WO2024020164A2 (fr) 2022-07-21 2024-01-25 Firefly Bio, Inc. Agonistes du récepteur des glucocorticoïdes et leurs conjugués
WO2024100449A1 (fr) * 2022-11-08 2024-05-16 Legochem Biosciences, Inc. Agonistes de sting
WO2024189481A1 (fr) 2023-03-10 2024-09-19 Novartis Ag Conjugués anticorps-médicament inhibiteurs de panras et leurs procédés d'utilisation
WO2024201004A1 (fr) 2023-03-24 2024-10-03 Prostate Cancer Research Thérapie combinatoire d'il-15

Also Published As

Publication number Publication date
EP3615080A1 (fr) 2020-03-04
JP2020517700A (ja) 2020-06-18
CN110799218A (zh) 2020-02-14
AR113224A1 (es) 2020-02-19

Similar Documents

Publication Publication Date Title
WO2018200812A1 (fr) Conjugués d'anticorps comprenant un agoniste de sting
US20210346387A1 (en) Antibody conjugates comprising toll-like receptor agonist
US20200164084A1 (en) Antibody conjugates comprising toll-like receptor agonist and combination therapies
US20210170043A1 (en) Dc-sign antibody conjugates comprising sting agonists
CA3165399A1 (fr) Utilisations d'anticorps anti-tgf-betas et inhibiteurs de point de controle pour le traitement des maladies proliferatives
US20230053449A1 (en) Dc-sign antibody drug conjugates
WO2020089815A1 (fr) Conjugués d'anticorps comprenant un agoniste de sting
US11701427B2 (en) Diels-alder conjugation methods

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18724677

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2019558397

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2018724677

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2018724677

Country of ref document: EP

Effective date: 20191128